Cerulean Pharma Inc.(CERU): For the most recent quarter end, Cerulean Pharma Inc. reported Annual Earnings of $-0.36. Based on the filings, last years Annual Earnings was, $-1.56. For the most recent quarter end, CERU reported a surprise Earnings per Share of 16.28% . The consensus estimate for current quarter is $-0.3 and for the current fiscal year, the estimate is $-1.6. For the Next fiscal year, the estimate is $-1.42 based on the consensus.
Cerulean Pharma Inc. has received $-0.3 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 1 Financial Advisor in the Stock Trading Firms. The EPS growth rate is projected at 23.08%. Cerulean Pharma Inc. reported better than expected with a surprise EPS of 16.28% or $0.07 during its most recent quarterly earnings. The Actual EPS was $-0.36 compared to the Estimated EPS of $-0.43.
Company has reported several Insider transactions to the SEC, on Feb 23, 2016, David R Walt (director) purchased 2,291 shares at 2.08 per share price.On Apr 9, 2015, Llc Cvf, (10% owner) purchased 333,333 shares at 6.00 per share price.
Cerulean Pharma Inc. (NASDAQ:CERU) witnessed a decline in the market cap on Wednesday as its shares dropped 5.93% or 0.08 points. After the session commenced at $1.33, the stock reached the higher end at $1.355 while it hit a low of $1.24. With the volume soaring to 1,035,633 shares, the last trade was called at $1.27. The company has a 52-week high of $4.33. The company has a market cap of $35 million and there are 27,435,680 shares in outstanding. The 52-week low of the share price is $0.6303.
Cerulean Pharma Inc. is a clinical-stage oncology-focused company. The Company manufactures therapeutics in the areas of oncology, cardiovascular, autoimmune, and inflammatory diseases as well as tumor cells. Cerulean Pharma Inc. is based in Cambridge, Massachusetts.